EUVIMEDEUVIMED entdecken
Crossref

Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment

Ye Wu, Jia-Yi Lin, Yu-Dong Zhou, Hai-Jun Liu, Sheng-Xin Lu, Xiao-Kun Zhang, Ying-Yun Guan, Dale G Nagle, Wei-Dong Zhang, Hong-Zhuan Chen, Xin Luan iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202303445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Ye Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shangh…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Adenosine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The application of oncolytic peptides has become a powerful approach to induce complete and long‐lasting remission in multiple types of carcinomas, as affirmed by the appearance of tumor‐associated antigens and adenosine triphosphate (ATP) in large quantities, which jumpstarts the cancer‐immunity cycle. However, the ATP breakdown product adenosine is a significant contributor to forming the immunosuppressive tumor microenvironment, which substantially weakens peptide‐driven oncolytic immunotherapy. In this study, a lipid‐coated micelle (CA@TLM) loaded with a stapled oncolytic peptide (PalAno) and an adenosine 2A receptor (A2AR) inhibitor (CPI‐444) is devised to enact tumor‐targeted oncolytic immunotherapy and to overcome adenosine‐mediated immune suppression simultaneously. The CA@TLM micelle accumulates in tumors with high efficiency, and the acidic tumor microenvironment prompts the rapid release of PalAno and CPI‐444. Subsequently, PalAno induces swift membrane lysis of tumor cells and the release of antigenic materials. Meanwhile, CPI‐444 blocks the activation of the immunosuppressive adenosine‐A2AR signaling pathway. This combined approach exhibits pronounced synergy at stalling tumor growth and metastasis in animal models for triple‐negative breast cancer and melanoma, providing a novel strategy for enhanced oncolytic immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentAdenosineAnimalsMiceHumansCell Line, TumorImmunotherapyReceptor, Adenosine A2AFemalePeptidesMicelles

Stichwörter der Autor:innen

adenosineadenosine 2A receptor inhibitoradenosine triphosphateimmunogenic cell deathimmunotherapyoncolytic peptide

Substanzen

AdenosineReceptor, Adenosine A2APeptidesMicelles

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Department of Chemistry and Biochemistry, College of Liberal Arts, University of Mississippi, University, MS, 38677, USA.
  • Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
  • Department of BioMolecular Sciences and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
  • School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.

ORCID-Profile: Xin Luan

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • China Postdoctoral Science Foundation
  • Oriental Scholars of Shanghai Universities
  • Jiangxi Province Thousand Talents Program
  • Young Talent Lifting Project of China Association of Chinese Medicine
  • Shanghai Rising-Star Program
  • Shanghai Sailing Program

Zitieren

APA

Wu, Y., Lin, J. Y., Zhou, Y. D., Liu, H. J., Lu, S. X., Zhang, X. K., Guan, Y. Y., Nagle, D. G., Zhang, W. D., Chen, H. Z., & Luan, X. (2024). Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303445

Vancouver

Wu Y, Lin JY, Zhou YD, Liu HJ, Lu SX, Zhang XK, et al. Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303445

BibTeX
@article{Wu2024,
  author = {Wu, Ye and Lin, Jia-Yi and Zhou, Yu-Dong and Liu, Hai-Jun and Lu, Sheng-Xin and Zhang, Xiao-Kun and Guan, Ying-Yun and Nagle, Dale G and Zhang, Wei-Dong and Chen, Hong-Zhuan and Luan, Xin},
  title = {Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202303445}
}
Kostenlos starten →